- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03280186
Measurement of Bladder Function Change In Patients With SVMs Before and After Surgical Intervention
Measurement of Bladder Function Change In Patients With Spinal Vascular Malformations Before and After Surgical Intervention
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient diagnosed with spinal vascular diseases including intradural arteriovenous malformation, intradural arteriovenous fistula, dural arteriovenous fistula, extradural arteriovenous malformation, paravertebral arteriovenous malformation, paravertebral arteriovenous fistula, cobbs' syndrome, other spinal arteriovenous metameric syndromes involve the spinal cord. patient not received surgical or interventional treatment before patient with normal cardiac, renal and hepatic function patient capable of understanding the content of the patient information / Informed Consent Form patient willing and able to participate in the registry
Exclusion Criteria:
- patient received surgical treatment or interventional treatment before patient is pregnant patient allergic to iodine patient unable to complete follow-up patient with cerebral lesions patient with other spinal lesions patient with cardiac, renal or hepatic dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients With SVMs
Patients with SVMs will be included in the group and undergo surgery.
|
The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
bladder function change in urodynamics
Time Frame: postoperative 3 months and 12 months
|
bladder function will be better in urodynamics after surgery.
|
postoperative 3 months and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Tongwen Ou, M.D, Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- otw-20170908
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurogenic Bladder Dysfunction Nos
-
Ulrich MehnertNCCR (National Center of Competence in Resaerch, Switzerland)CompletedHealthy | Neurogenic Bladder Dysfunction Nos | Nonneurogenic Neurogenic Bladder DysfunctionSwitzerland
-
Coloplast A/SCompletedNeurogenic Bladder Dysfunction NosDenmark, France, Germany, Norway, Sweden
-
Baylor College of MedicineU.S. Department of EducationTerminatedSpinal Cord Injury | Neurogenic Bladder Dysfunction NosUnited States
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland
-
APOGEPHA Arzneimittel GmbHCompletedUrologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor FunctionRomania, Austria, Germany
-
Swiss Paraplegic Centre NottwilCompletedNeurogenic Bladder DysfunctionSwitzerland
-
JW PharmaceuticalCompletedNeurogenic Bladder | Voiding DysfunctionKorea, Republic of
-
The Methodist Hospital Research InstituteCompleted
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionItaly, Belgium, Switzerland, Brazil
Clinical Trials on surgery
-
University of AarhusCompletedAcute Post Operative Pain | Chronic Postsurgical PainDenmark
-
International Study Group on Minimally Invasive...Fondazione CARIT; LOGIX S.r.l.Unknown
-
Peking Union Medical College HospitalCompletedPancreatic Neuroendocrine TumorsChina
-
Sunnybrook Health Sciences CentreMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsCompleted
-
Hospital Central de la Defensa Gómez UllaClinica Universidad de Navarra, Universidad de NavarraEnrolling by invitationRectal Cancer | PROM | Functional Bowel DisorderSpain
-
Shanghai Zhongshan HospitalUnknownCarcinoma, Pancreatic Ductal | Circulating Tumor CellsChina
-
The Christie NHS Foundation TrustUniversity of ManchesterRecruitingQuality of Life | Lung NeoplasmsUnited Kingdom
-
Spinal Surgery Clinic, SträngnäsCompletedLow Back Pain | Pelvic Pain
-
University of Campania "Luigi Vanvitelli"CompletedOncologic Disorders | Nutritional and Metabolic Diseases
-
University Hospital, GrenobleCompleted